Search hospitals > Ontario > TORONTO
University Health Network
Claim this profileTORONTO, Ontario M5G 2C4
Global Leader in Prostate Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Depression
Conducts research for Breast Cancer
541 reported clinical trials
60 medical researchers
Summary
University Health Network is a medical facility located in TORONTO, Ontario. This center is recognized for care of Prostate Cancer, Cancer, Lung Cancer, Depression, Breast Cancer and other specialties. University Health Network is involved with conducting 541 clinical trials across 695 conditions. There are 60 research doctors associated with this hospital, such as Lillian Siu, MD, Marcus Butler, Anna Spreafico, MD PhD, and Peter Chung, MD.Area of expertise
1Prostate Cancer
Global LeaderStage IV
2Cancer
Global LeaderStage IV
TP53 positive
HER2 positive
Top PIs
Lillian Siu, MDPrincess Margaret Cancer Centre6 years of reported clinical research
Studies Lung Cancer
Studies Melanoma
18 reported clinical trials
42 drugs studied
Marcus ButlerPrincess Margaret Cancer Centre8 years of reported clinical research
Studies Melanoma
Studies Cancer
15 reported clinical trials
27 drugs studied
Anna Spreafico, MD PhDPrincess Margaret Cancer Centre6 years of reported clinical research
Studies Squamous Cell Carcinoma
Studies Cancer
12 reported clinical trials
23 drugs studied
Peter Chung, MDUniversity Health Network, Princess Margaret Hospital2 years of reported clinical research
Studies Prostate Cancer
Studies Testicular Cancer
9 reported clinical trials
16 drugs studied
Clinical Trials running at University Health Network
Breast Cancer
Cancer
Heart Failure
Prostate Cancer
Cardiotoxicity
Melanoma
Multiple Myeloma
Soft Tissue Sarcoma
Bladder Cancer
Non-Hodgkin's Lymphoma
Sentinel Lymph Node Biopsy
for Breast Cancer
This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients who have had chemotherapy as a first treatment using a non-inferiority design. Patients with operable breast cancer treated with chemotherapy and eligible for SLNB will be included in the study. During surgery, ICG will be injected and used to identify fluorescent sentinel nodes using a hand-held imaging camera; radiotracer and blue dye will also be used as per standard protocols. Intraoperative and clinicopathologic outcomes such as complications, characteristics of nodes, false negative rates and feasibility will be assessed. Patients will be asked to complete standardized patient reported outcome questionnaires (Breast-Q, FACT-B+4, VAS) to define the patient experience with this novel technique.
Recruiting1 award N/A6 criteria
Anakinra
for Breast Cancer
This study will examine changes in the tumor microenvironment (TME) induced by 14 days of pre-operative IL-1-inhibiting therapy among patients with early breast cancer (including TNBC and ER-low positive). Key immune biomarkers (TILs, TAMs, NK cells, IL1\[beta\] and inflammasome component expression) will be evaluated at baseline and following 14 days of IL-1 antagonist therapy (Anakinra) using paired tissue specimens.
Recruiting1 award Phase 23 criteria
PEM vs Liquid Biopsy
for Breast Cancer
The goal of this research study is to evaluate the performance of two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to assess whether findings from the combination or each individual test can assist radiologists in visualizing and characterizing beast abnormalities. Liquid Biopsy is a blood test that can detect early tumours in patients with malignancies, while PEM is an imaging tool equipped with a high-resolution camera that uses a low dose of injected positron emitting isotope to locate breast tumours. Participation in this study entails a blood draw for Liquid Biopsy test and a PEM imaging exam before undergoing a magnetic resonance imaging (MRI) - guided biopsy for a suspicious breast lesion. If PEM and/or Liquid Biopsy provide accurate information to assist radiologists in visualizing and characterizing breast abnormalities, this method may serve as the first step towards establishing these genomic and new imaging technologies as new diagnostic modalities and ultimately reduce the unnecessary biopsies and anxiety in high-risk populations.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University Health Network?
Where is University Health Network located?
Who should I call to ask about financial aid or insurance network?
What insurance does University Health Network accept?
What awards or recognition has University Health Network received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.